ibrutinib + docetaxel

**Ibrutinib + docetaxel** is a combination of two pharmaceutical agents: **ibrutinib**, an oral, first-in-class covalent inhibitor of Bruton’s tyrosine kinase (BTK), and **docetaxel**, an intravenous cytotoxic antimicrotubule agent of the taxane class. Ibrutinib is primarily used to target B-cell malignancies by interrupting B-cell antigen receptor signaling, whereas docetaxel disrupts microtubule networks, leading to cell death during mitosis. Preclinical rationale and some clinical studies (e.g., in advanced, previously treated gastric adenocarcinoma) have evaluated the safety and efficacy of this combination, particularly with the hypothesis that combining a targeted BTK inhibitor with a chemotherapeutic taxane may offer synergistic antitumor effects. The combination is investigational and not approved for any indication, having been studied mainly in early-phase clinical trials for advanced solid tumors, most notably advanced gastric (and gastroesophageal junctional) adenocarcinoma, where it demonstrated feasibility but no clinically meaningful efficacy advantage over standard therapy[1][2].